ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

BACKGROUND: Overexpression of ABC transporters is a big challenge on cancer therapy which will lead cancer cells resistance to a series of anticancer drugs. Gedatolisib is a dual PI3K and mTOR inhibitor which is under clinical evaluation for multiple types of malignancies, including colorectal cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Changfu, Xing, Wenge, Yu, Haipeng, Zhang, Weihao, Si, Tongguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885361/
https://www.ncbi.nlm.nih.gov/pubmed/33593355
http://dx.doi.org/10.1186/s12935-021-01800-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885361/
https://www.ncbi.nlm.nih.gov/pubmed/33593355
http://dx.doi.org/10.1186/s12935-021-01800-7

Ejemplares similares